订阅泛读方向 订阅泛读期刊
  • 我的关注
  • 我的关注
  • {{item.title}}


  • {{item.title}}


  • {{item.subscribe_count}}人订阅



Respiratory Immunization With a Whole Cell Inactivated Vaccine Induces Functional Mucosal Immunoglobulins Against Tuberculosis in Mice and Non-human Primates


  • 影响因子:4.30
  • DOI:10.3389/fmicb.2020.01339
  • 作者列表:"Nacho Aguilo","Nacho Aguilo","Santiago Uranga","Santiago Uranga","Elena Mata","Elena Mata","Raquel Tarancon","Raquel Tarancon","Ana Belén Gómez","Ana Belén Gómez","Dessislava Marinova","Dessislava Marinova","Isabel Otal","Isabel Otal","Marta Monzón","Juan Badiola","Dolores Montenegro","Eugenia Puentes","Esteban Rodríguez","Richard A. W. Vervenne","Claudia C. Sombroek","Frank A. W. Verreck","Carlos Martín","Carlos Martín","Carlos Martín
  • 发表时间:2020-06-18

Vaccination through the natural route of infection represents an attractive immunization strategy in vaccinology. In the case of tuberculosis, vaccine delivery by the respiratory route has regained interest in recent years, showing efficacy in different animal models. In this context, respiratory vaccination triggers lung immunological mechanisms which are omitted when vaccines are administered by parenteral route. However, contribution of mucosal antibodies to vaccine- induced protection has been poorly studied. In the present study, we evaluated in mice and non-human primates (NHP) a novel whole cell inactivated vaccine (MTBVAC HK), by mucosal administration. MTBVAC HK given by intranasal route to BCG-primed mice substantially improved the protective efficacy conferred by subcutaneous BCG only. Interestingly, this improved protection was absent in mice lacking polymeric Ig receptor (pIgR), suggesting a crucial role of mucosal secretory immunoglobulins in protective immunity. Our study in NHP confirmed the ability of MTBVAC HK to trigger mucosal immunoglobulins. Importantly, in vitro assays demonstrated the functionality of these immunoglobulins to induce M. tuberculosis opsonization in the presence of human macrophages. Altogether, our results suggest that mucosal immunoglobulins can be induced by vaccination to improve protection against tuberculosis and therefore, they represent a promising target for next generation tuberculosis vaccines.


通过自然感染途径接种疫苗代表了疫苗学中一种有吸引力的预防接种。在结核病的情况下,近年来通过呼吸途径递送疫苗重新获得了兴趣,在不同的动物模型中显示出疗效。在这种情况下,呼吸道疫苗接种触发肺免疫机制,当疫苗通过胃肠外途径给药时,这些机制被省略。然而,粘膜抗体对疫苗诱导的保护作用的贡献研究甚少。在本研究中,我们通过粘膜给药在小鼠和非人灵长类动物 (NHP) 中评价了一种新型全细胞灭活疫苗 (MTBVAC HK)。通过鼻内途径给予 BCG 致敏小鼠 MTBVAC HK 可显著提高仅皮下 BCG 赋予的保护效力。有趣的是,这种改善的保护作用在缺乏聚合 Ig 受体 (pIgR) 的小鼠中缺失,提示粘膜分泌免疫球蛋白在保护性免疫中的关键作用。我们在 NHP 中的研究证实了 MTBVAC HK 触发粘膜免疫球蛋白的能力。重要的是,体外试验证明了这些免疫球蛋白在人巨噬细胞存在的情况下诱导结核分枝杆菌调理的功能。总之,我们的结果表明,粘膜免疫球蛋白可以通过疫苗接种来诱导,以提高对结核病的保护作用,因此,它们代表了下一代结核病疫苗的一个有希望的靶点。



作者列表:["Ria Goswami","Ashley N. Nelson","Joshua J. Tu","Maria Dennis","Liqi Feng","Amit Kumar","Jesse Mangold","Riley J. Mangan","Cameron Mattingly","Alan D. Curtis","Veronica Obregon-Perko","Maud Mavigner","Justin Pollara","George M. Shaw","Katharine J. Bar","Ann Chahroudi","Kristina De Paris","Cliburn Chan","Koen K. A. Van Rompay","Sallie R. Permar"]

METHODS:Novel interventions that do not rely on daily adherence to ART are needed to achieve sustained viral remission for perinatally infected children, who currently rely on lifelong ART. Considering the risks and expense associated with ART interruption trials, the identification of biomarkers of viral rebound will prioritize promising therapeutic intervention strategies, including anti-HIV Env protein therapeutics. However, comprehensive studies to identify those biomarkers are logistically challenging in human infants, demanding the need for relevant nonhuman primate models of HIV rebound. In this study, we developed an infant RM model of oral infection with simian-human immunodeficiency virus expressing clade C HIV Env and short-term ART followed by ATI, longitudinally characterizing the immune responses to viral infection during ART and after ATI. Additionally, we compared this infant RM model to an analogous adult RM rebound model and identified virologic and immunologic correlates of the time to viral rebound after ATI.To achieve long-term viral remission in human immunodeficiency virus (HIV)-infected children, novel strategies beyond early antiretroviral therapy (ART) will be necessary. Identifying clinical predictors of the time to viral rebound upon ART interruption will streamline the development of novel therapeutic strategies and accelerate their evaluation in clinical trials. However, identification of these biomarkers is logistically challenging in infants, due to sampling limitations and the potential risks of treatment interruption. To facilitate the identification of biomarkers predicting viral rebound, we have developed an infant rhesus macaque (RM) model of oral simian-human immunodeficiency virus (SHIV) SHIV.CH505.375H.dCT challenge and analytical treatment interruption (ATI) after short-term ART. We used this model to characterize SHIV replication kinetics and virus-specific immune responses during short-term ART or after ATI and demonstrated plasma viral rebound in 5 out of 6 (83%) infants. We observed a decline in humoral immune responses and partial dampening of systemic immune activation upon initiation of ART in these infants. Furthermore, we monitored SHIV replication and rebound kinetics in infant and adult RMs and found that both infants and adults demonstrated equally potent virus-specific humoral immune responses. Finally, we validated our models by confirming a well-established correlate of the time to viral rebound, namely, the pre-ART plasma viral load, as well as identified additional potential humoral immune correlates. Thus, this model of infant ART and viral rebound can be used and further optimized to define biomarkers of viral rebound following long-term ART as well as to preclinically assess novel therapies to achieve a pediatric HIV functional cure.

翻译标题与摘要 下载文献
作者列表:["E. R. Job","T. Ysenbaert","A. Smet","A. Van Hecke","L. Meuris","H. Kleanthous","X. Saelens","T. U. Vogel"]

METHODS:There is a pressing need for next-generation influenza vaccine strategies that are better able to manage antigenic drift and the cocirculation of multiple drift variants and that consistently improve vaccine effectiveness. Influenza virus NA is a key target antigen as a component of a next-generation vaccine in the influenza field, with evidence for a role in protective immunity in humans. However, mechanisms of protection provided by antibodies directed to NA remain largely unexplored. Herein, we show that antibody Fc interaction with Fcγ receptors (FcγRs) expressed on effector cells contributes to viral control in a murine model of influenza. Importantly, a chimeric mouse-human IgG1 with no direct antiviral activity was demonstrated to solely rely on FcγRs to protect mice from disease. Therefore, antibodies without NA enzymatic inhibitory activity may also play a role in controlling influenza viruses and should be of consideration when designing NA-based vaccines and assessing immunogenicity.Influenza virus neuraminidase (NA) has been under intense study recently as a vaccine antigen, yet there remain unanswered questions regarding the immune response directed toward NA. Antibodies (Abs) that can inhibit NA activity have been shown to aid in the control of disease caused by influenza virus infection in humans and animal models, yet how and if interactions between the Fc portion of anti-NA Abs and Fcγ receptors (FcγR) contribute to protection has not yet been extensively studied. Herein, we show that poly- and monoclonal anti-NA IgG antibodies with NA inhibitory activity can control A(H1N1)pdm09 infection in the absence of FcγRs, but FcγR interaction aided in viral clearance from the lungs. In contrast, a mouse-human chimeric anti-NA IgG1 that was incapable of mediating NA inhibition (NI) solely relied on FcγR interaction to protect transgenic mice (with a humanized FcγR compartment) against A(H1N1)pdm09 infection. As such, this study suggests that NA-specific antibodies contribute to protection against influenza A virus infection even in the absence of NI activity and supports protection through multiple effector mechanisms.

翻译标题与摘要 下载文献
作者列表:["Tiziana Lazzarotto","Daniel Blázquez-Gamero","Marie-Luce Delforge","Ina Foulon","Suzanne Luck","Suzanne Luck","Susanne Modrow","Marianne Leruez-Ville"]

METHODS:Maternal primary and non-primary cytomegalovirus (CMV) infection during pregnancy can result in in utero transmission to the developing fetus. Congenital CMV (cCMV) can result in significant morbidity, mortality or long-term sequelae, including sensorineural hearing loss, the most common sequela. As a leading cause of congenital infections worldwide, cCMV infection meets many of the criteria for screening. However, currently there are no universal programs that offer maternal or neonatal screening to identify infected mothers and infants, no vaccines to prevent infection, and no efficacious and safe therapies available for the treatment of maternal or fetal CMV infection. Data has shown that there are several maternal and neonatal screening strategies, and diagnostic methodologies, that allow the identification of those at risk of developing sequelae and adequately detect cCMV. Nevertheless, many questions remain unanswered in this field. Well-designed clinical trials to address several facets of CMV treatment (in pregnant women, CMV-infected fetuses and both symptomatic and asymptomatic neonates and children) are required. Prevention (vaccines), biology and transmission factors associated with non-primary CMV, and the cost-effectiveness of universal screening, all demand further exploration to fully realize the ultimate goal of preventing cCMV. In the meantime, prevention of primary infection during pregnancy should be championed to all by means of hygiene education.